Showing 1021-1030 of 10531 results for "".
Cutaneous Oncology in 2024
https://practicaldermatology.com/conferences/maui-derm-2024/cutaneous-oncology-in-2024/20266/Resident Of Distinction Award-winner Banu Farabi, MD, a PGY-3 resident at New York Medical College, talks about a review she attended highlighting the latest therapeutic approaches to treating conditions such as actinic keratosis and several different types of skin cancer, as well as an overview ofDWTV Extra: Phase 3 Data on Roflumilast for AD, PsO
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-phase-3-data-on-roflumilast-for-ad-pso/35925/Study investigator Melinda Gooderham, MD, talks about the Phase 3 trials of roflumilast cream 0.15% for adults and children down to age 6 with atopic dermatitis and roflumilast foam 0.3% for patients older than 12 with psoriasis of the scalp and body.Connective Tissue Disorders Update 2025: Dr. Vleugels
https://practicaldermatology.com/programs/practical-dermatology/connective-tissue-disorders-update-2025-dr-vleugels/32673/Ruth Ann Vleugels, MD, PhD, recaps her presentation, "Connective Tissue Disorders Update 2025" at Maui Derm 2025. Dr. Vleugels discussed a new therapeutic for systemic lupus, a new FDA-approved option for dermatomyositis, JAK inhibitors, and more.Taking Action: Quality of Care in AD
https://practicaldermatology.com/topics/atopic-dermatitis/taking-action-quality-of-care-in-ad/19881/Beyond identifying barriers to AD patient care, the Quality of Care in Atopic Dermatitis initiative presents potential solutions. Eric Simpson, MD, MCR outlines some key strategies for improving care and emphasizes that some simple steps can make a big difference.Evolutions and Revolutions in HS
https://practicaldermatology.com/topics/rare-disease/evolutions-and-revolutions-in-hs/19726/The past decade has seen significant advances in the understanding of hidradenitis suppurativa pathogenesis, informing research into novel treatment approaches, such as biologics, and expanded indications for existing pharmacologic agents. Ali Alikhan, MD reviews the evolving landscape in HS and revThread Lifting 4.0
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/thread-lifting-40/19603/Today’s thread lifts bring more to the table than previous iterations. Older threads lifted sagging facial tissue, but now they are absorbable and biostimulatory, which means they can lift and add volume to the face and also aid in scar remodelling, explains Hooman Khorasani, MD.Chemical Peels for Lip Augmentation
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/chemical-peels-for-lip-augmentation--dcwokite/19585/For patients looking for natural results or who want an alternative to hyaluronic acid fillers and needles, deep chemical peels are an excellent alternative for lip augmentation, explains Kachiu Lee, MD. She shares treatment pearls and discusses the kind of results patients can expect.Heliocare in Practice
https://practicaldermatology.com/topics/practice-management/heliocare-in-practice/19220/Polypodium leucotomos extract, which is derived from a tropical fern, offers benefits to users by minimizing some of the damage to the skin caused by exposure to visible light—UVA and UVB radiation—as well as invisible infrared light. Vivian Bucay, MD, discusses its activity and its role as a dispenCSF 2022 Highlights
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/csf-2022-highlights/20162/Joel Schlessinger, MD says the 2022 Cosmetic Surgery Forum was a success. The unique format of the meeting encourages presenters and audience members to interact and engage in lively discussions that allow attendees to leave the meeting with ideas they can use in their practices immediately.New Drug Developments in Dermatology
https://practicaldermatology.com/topics/skin-cancer-photoprotection/new-drug-developments-in-dermatology/19971/Despite the COVID pandemic, the FDA had a nearly record year in drug approvals, says Vinod Nambudiri, MD, MBA, which has translated to new developments in dermatology. He discusses approvals of tirbanibulin 1% ointment for actinic keratoses and clascoterone cream 1% for acne, and how they fit into t